1-carbethoxymethyl 1,2,3,4-tetrahydroisoquinoline | 1424-84-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1-carbethoxymethyl 1,2,3,4-tetrahydroisoquinoline
• 英文别名: Ethyl 2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetate
• CAS: 1424-84-6
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: JNBDCWJGYVMSIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-carbethoxymethyl 1,2,3,4-tetrahydroisoquinoline 在 二甲胺 、 N,N-二异丙基乙胺 、 三氟乙酸酐 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 1(R,S)-(N,N-Dimethylcarbamoylmethyl)-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives

  摘要：

  本发明涉及式(I)的化合物，其中X为CH或N；Y为可选择的单不饱和C.sub.3-C.sub.5烷基，可选择地取代为C.sub.1-C.sub.4烷基或亚甲基；R.sup.1为H；C.sub.1-C.sub.4烷基，可选择地取代为C.sub.1-C.sub.4烷氧基，OH，NR.sup.5R.sup.6，CONR.sup.5R.sup.6，C.sub.3-C.sub.6环烷基或芳基；或C.sub.3-C.sub.6烯基；R.sup.2为H；C.sub.1-C.sub.4烷基，可选择地取代为C.sub.1-C.sub.4烷氧基，OH，NR.sup.5R.sup.6，CONR.sup.5R.sup.6，C.sub.3-C.sub.6环烷基或芳基；或CONR.sup.5R.sup.6；R.sup.3和R.sup.4各自独立地选自H；C.sub.1-C.sub.4烷基，可选择地取代为NR.sup.5R.sup.6；C.sub.1-C.sub.4烷氧基；卤素；CONR.sup.5R.sup.6和芳基；R.sup.5和R.sup.6各自独立地选自H和C.sub.1-C.sub.4烷基；m和n各自独立地为1、2或3；这些化合物是有效且选择性的凝血酶抑制剂，可用于治疗深静脉血栓形成等疾病。

  公开号：

  US05750520A1
• 作为产物：
  描述：

  2-(2-溴乙基)苯甲醛 在 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 36.0h， 生成 1-carbethoxymethyl 1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Tandem SN2-Michael reactions for the preparation of simple five- and six-membered-ring nitrogen and sulfur heterocycles

  摘要：

  A one-pot tandem S(N)2-Michael addition sequence has been developed for the preparation of five-membered- and six-membered-ring nitrogen and sulfur heterocycles from 6- or 7-halo-2-alkenoate esters. Nitrogen-containing rings are prepared by reaction of the omega-halo-2-alkenoate ester with a primary amine in the presence of triethylamine. The sulfur analogues are generated by thiourea displacement of the halide followed by base hydrolysis of the isothiouronium salt. Yields are routinely in the 60-80% range. Experiments are described which elucidate the chronology of the reaction sequences. Ring size and steric hindrance to the initial substitution reaction appear to be the only limitations of the procedure.

  DOI：

  10.1021/jo00032a025

文献信息

• 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and
  申请人：Sanofi Winthrop, Inc.

  公开号：US05656629A1

  公开（公告）日：1997-08-12

  6-Substituted pyrazolo[3,4 -d]pyrimidin-4-one derivatives, pharmaceutical compositions containing them and methods for effecting c-GMP-phosphodiesterase inhibition and for treating heart failure and/or hypertension.

  6-取代嘧啶并[3,4 -d]嘧啶-4-酮衍生物，含有它们的药物组合物以及用于影响c-GMP-磷酸二酯酶抑制和治疗心力衰竭和/或高血压的方法。
• 一种构建四氢异喹啉类化合物的方法
  申请人：中国科学院福建物质结构研究所

  公开号：CN110452169B

  公开（公告）日：2021-02-19

  本申请公开了一种化合物，具有式I所示的结构式。以及该化合物的制备方法，该方法利用氨基导向的苯乙胺邻位C(sp2)–H键烯基化环化反应，从而获得了高效合成四氢异喹啉类化合物的方法。
• Antithrombotic amidinotetrahydropyridylalanine derivatives
  申请人：Pfizer Inc.

  公开号：US05798352A1

  公开（公告）日：1998-08-25

  This invention is directed to compounds of formula (I), ##STR1## pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates of either entity, wherein Y is optionally monounsaturated C.sub.3 -C.sub.5 alkylene optionally substituted with C.sub.1 -C.sub.4 alkyl or methylene; R.sup.1 is H; C.sub.1 -C.sub.4 alkyl optionally substituted with C.sub.1 -C.sub.4 alkoxy, OH, NR.sup.5 R.sup.6, CONR.sup.5 R.sup.6, C.sub.3 -C.sub.6 cycloalkyl or aryl; or C.sub.3 -C.sub.6 alkenyl; R.sup.2 is H; C.sub.1 -C.sub.4 alkyl optionally substituted with C.sub.1 -C.sub.4 alkoxy, OH, NR.sup.5 R.sup.6, CONR.sup.5 R.sup.6, C.sub.3 -C.sub.6 cycloalkyl or aryl; or CONR.sup.5 R.sup.6 ; R.sup.3 and R.sup.4 are each independently selected from H; C.sub.1 -C.sub.4 alkyl optionally substituted with NR.sup.5 R.sup.6 ; C.sub.1 -C.sub.4 alkoxy; halo; CONR.sup.5 R.sup.6 and aryl; aryl is phenyl optionally substituted with one, two or three substituents independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, OH, halo and CF.sub.3 ; R.sup.5 and R.sup.6 are each independently selected from H and C.sub.1 -C.sub.4 alkyl; and m and n are each independently 1, 2 or 3; which are potent and selective thrombin inhibitors useful in the treatment of inter alia, deep vein thrombosis; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; restenosis and occlusion following angioplasty; or neurodegenerative disorders.

  本发明涉及化合物的结构式(I) ##STR1## 及其药学上可接受的盐和任一实体的药学上可接受的溶剂结晶体，其中Y是可选择地具有C.sub.3 -C.sub.5的不饱和的烷基，可选择地取代有C.sub.1 -C.sub.4烷基或亚甲基; R.sup.1是H; 可选择地取代有C.sub.1 -C.sub.4烷基的C.sub.1 -C.sub.4烷氧基、OH、NR.sup.5 R.sup.6、CONR.sup.5 R.sup.6、C.sub.3 -C.sub.6环烷基或芳基; 或C.sub.3 -C.sub.6烯基; R.sup.2是H; 可选择地取代有C.sub.1 -C.sub.4烷基的C.sub.1 -C.sub.4烷氧基、OH、NR.sup.5 R.sup.6、CONR.sup.5 R.sup.6、C.sub.3 -C.sub.6环烷基或芳基; 或CONR.sup.5 R.sup.6; R.sup.3和R.sup.4各自独立地选择自H; 可选择地取代有NR.sup.5 R.sup.6的C.sub.1 -C.sub.4烷基; C.sub.1 -C.sub.4烷氧基; 卤素; CONR.sup.5 R.sup.6和芳基; 芳基是苯基，可选择地取代有一个、两个或三个从C.sub.1 -C.sub.4烷基、C.sub.1 -C.sub.4烷氧基、OH、卤素和CF.sub.3中独立选择的取代基; R.sup.5和R.sup.6各自独立地选择自H和C.sub.1 -C.sub.4烷基; m和n各自独立地选择为1、2或3; 这些化合物是有效且选择性的凝血酶抑制剂，在治疗包括深静脉血栓形成、溶栓治疗后再闭塞、慢性动脉阻塞、周围血管疾病、急性心肌梗死、不稳定性心绞痛、心房颤动、血栓性中风、短暂性缺血发作、血管成形术后再狭窄和闭塞，或神经退行性疾病等方面有用。
• Eight-Membered Palladacycles Derived from the Insertion of Olefins into the Pd−C Bond of Ortho-Palladated Pharmaceuticals Phenethylamine and Phentermine. Synthesis of Stable Heck-Type Intermediates Containing Accessible β-Hydrogens and Its Use in the Synthesis of 2-Styrylphenethylamines, Tetrahydroisoquinolines, and Eight-Membered Cyclic Amidines
  作者：José Vicente、Isabel Saura-Llamas、José-Antonio García-López、Delia Bautista

  DOI：10.1021/om100738z

  日期：2010.10.11

  the product of its insertion into the Pd−C bond, [PdC,N-CH(R′)CH2C6H4CH2CR2NH2-2}(μ-X)]2 (olefin = CH2═CHR′; R = H, X = Br, R′ = C(O)Me (1a), CO2Et (1c); R = Me, X = Cl, R′ = C(O)Me (1b), CO2Et (1d)) and [PdC,N-CH(C5H8)CHC6H4(CH2CMe2NH2)-2}(μ-Cl)]2 (olefin = norbornene, C5H8; 1e) or (2) the decomposition products of 1, i.e., Pd(0) and the complexes containing the arylated olefin, trans-[PdX2(NH2CR2CH2C6H4CH═CHPh-2)2]

  衍生自苯乙胺和芬特明的邻位金属配合物，[Pd（C，N -C 6 H 4 CH 2 CR 2 NH 2 -2）（μ-X）] 2（R = H，X = Br（A）; R = Me，X = Cl（B）），与烯烃反应，得到（1）其插入Pd-C键的产物[Pd C，N -CH（R'）CH 2 C 6 H 4 CH 2 CR 2 NH 2 -2}（μ-X）] 2（烯烃= CH 2 = CHR'; R = H，X = Br的，R'= C（O）Me（1A），CO 2Et（1c）; R = Me，X = Cl，R'= C（O）Me（1b），CO 2 Et（1d））和[Pd C，N -CH（C 5 H 8）CHC 6 H 4（CH 2 CMe 2 NH 2）-2}（μ-Cl）] 2（烯烃=降冰片烯，C 5 H 8；1e）或（2）1的分解产物，即Pd（0）和含有芳基化烯烃的配合物，反式-[PdX 2（NH 2
• The Reaction of 3,4-Dihydroisoquinolines With Malonic Acid and Its Derivatives
  作者：Jeffrey C. Pelletier、Michael P. Cava

  DOI：10.1055/s-1987-33431

  日期：——

  The reaction of various 3,4-dihydroisoquinolines with malonic acid gives the corresponding 1,2,3,4-tetrahydro-1-isoquinolineacetic acids in good yield, while the reaction with cyanoacetic acid and malonic acid half ethyl ester affords 1,2,3,4-tetrahydro-1-isoquinoline acetonitriles and 1,2,3,4-tetrahydro-1-isoquinolineacetic esters respectively. The use of other 1,3-dicarbonyls which cannot decarboxylate in this reaction affords the normal addition products.

  各种 3,4-二氢异喹啉与丙二酸反应可以得到相应的 1,2,3,4-四氢-1-异喹啉乙酸，收率很高，而与氰基乙酸和丙二酸半乙酯反应则可以分别得到 1,2,3,4-四氢-1-异喹啉乙腈和 1,2,3,4-四氢-1-异喹啉乙酸酯。在此反应中使用其他不能脱羧的 1,3-二羰基，可得到正常的加成产物。